Your browser doesn't support javascript.
loading
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy.
Pinato, David J; Kaseb, Ahmed; Wang, Yinghong; Saeed, Anwaar; Szafron, David; Jun, Tomi; Dharmapuri, Sirish; Naqash, Abdul Rafeh; Muzaffar, Mahvish; Navaid, Musharraf; Khan, Uqba; Lee, ChiehJu; Bulumulle, Anushi; Yu, Bo; Paul, Sonal; Fessas, Petros; Nimkar, Neil; Bettinger, Dominik; Hildebrand, Hannah; Pressiani, Tiziana; Abugabal, Yehia I; Personeni, Nicola; Huang, Yi-Hsiang; Lozano-Kuehne, Jingky; Rimassa, Lorenza; Ang, Celina; Marron, Thomas U.
Afiliação
  • Pinato DJ; Department of Surgery and Cancer, Imperial College London, London, UK david.pinato@imperial.ac.uk.
  • Kaseb A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang Y; Department of Gastroenterology, Hepatology & Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • Saeed A; Division of Medical Oncology, Kansas University Cancer Center, Kansas City, Kansas, USA.
  • Szafron D; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jun T; Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital School of Medicine, New York, New York, USA.
  • Dharmapuri S; Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital School of Medicine, New York, New York, USA.
  • Naqash AR; National Cancer Institute, Bethesda, Maryland, USA.
  • Muzaffar M; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Navaid M; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Khan U; Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, Ithaca, New York, USA.
  • Lee C; Division of Gastroenterology and Hepatology, Department of Medicine at Taipei Veterans General Hospital and Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Bulumulle A; Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA.
  • Yu B; Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, Ithaca, New York, USA.
  • Paul S; Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, Ithaca, New York, USA.
  • Fessas P; Surgery and Cancer, Imperial College London, London, UK.
  • Nimkar N; Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, Ithaca, New York, USA.
  • Bettinger D; Department of Medicine II, Faculty of Medicine, Medical Center University of Freiburg, Freiburg, Baden-Württemberg, Germany.
  • Hildebrand H; Division of Medical Oncology, Kansas University Cancer Center, Kansas City, Kansas, USA.
  • Pressiani T; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy, Rozzano, Lombardia, Italy.
  • Abugabal YI; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Personeni N; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy, Rozzano, Lombardia, Italy.
  • Huang YH; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, Milan, Italy.
  • Lozano-Kuehne J; Division of Gastroenterology and Hepatology, Department of Medicine at Taipei Veterans General Hospital and Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Rimassa L; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Ang C; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy, Rozzano, Lombardia, Italy.
  • Marron TU; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, Milan, Italy.
J Immunother Cancer ; 8(2)2020 10.
Article em En | MEDLINE | ID: mdl-33028690
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Corticosteroides / Carcinoma Hepatocelular / Inibidores de Checkpoint Imunológico / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Corticosteroides / Carcinoma Hepatocelular / Inibidores de Checkpoint Imunológico / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido